Momentum Program

When your patients join the Momentum Program, they receive free tips, suggestions, and if eligible, money-saving offers* delivered right to their inbox or mailbox.

dollar signSavings card

Eligible patients may qualify to save up to $50 every month for a full year for a maximum savings of $600.*

recipe cardRecipes

Patients receive a list of bladder-irritating foods to avoid, plus recipes and other helpful information.


Patients receive exercises that can help them manage OAB symptoms.

For eligibility restrictions, program enrollment, and savings card activation, visit the Momentum website.

*Subject to eligibility. Restrictions may apply.

Patient is responsible for the first $20 plus any differential over $70 on each prescription.


This offer is not valid for patients whose prescription claims are reimbursed, in whole or in part, by any state or federal government program, including, but not limited to, Medicaid, Medicare, Medigap, Department of Defense (DoD), Veterans Affairs (VA), TRICARE, CHAMPUS, Puerto Rico Government Health Insurance, or any State Patient or Pharmaceutical Assistance Program. This offer is void where prohibited by law. Certain rules and restrictions apply.

NEXT: Access Program and Services

VESIcare Support Solutions

VESIcare Support Solutions, a component of Astellas Pharma Support SolutionsSM, offers access and reimbursement services to help patients and their healthcare providers overcome challenges to accessing VESIcare. VESIcare Support Solutions provides information regarding patient healthcare coverage options and financial assistance programs to help patients with financial needs. To learn more, visit

financial supportAstellas Patient
Program (PAP)

VESIcare Support Solutions can determine whether a patient is eligible to receive VESIcare at no cost.


VESIcare Support Solutions offers Benefits Verification assistance to evaluate your patient's insurance coverage for VESIcare.

prescriptionPrior Authorization

VESIcare Support Solutions will provide Prior Authorization (PA) assistance when a healthcare provider makes a direct request for PA or Benefits Verification assistance and a prior authorization is required.

Helpful information on VESIcare Support Solutions and PAP criteria is also available at: (800) 477-6472

Monday - Friday,
9 AM - 8 PM ET

Astellas Patient Assistance Program (PAP)

The Astellas Patient Assistance Program provides VESIcare at no cost to patients who meet the program eligibility requirements. To learn more, visit


Approved patients can receive direct shipments.

online toolAPSS eService

An online tool offering helpful alerts and email reminders.


Simple re-enrollment process for patients who continue to meet the eligibility criteria.

Patients may receive VESIcare at no cost if they meet the following eligibility criteria:

  • Have been prescribed VESIcare for an FDA-approved indication,
  • Are uninsured or have insurance that excludes coverage for VESIcare,
  • Have a verifiable shipping address in the United States, and
  • Have a gross income of ≤2.5x the federal poverty level
NEXT: 3-Day Bladder Diary

For Your Patients: 3-Day Bladder Diary

Download this bladder diary to help your patients keep track and get a better sense of their day-to-day symptoms.


Indication and Dosage

VESIcare® (solifenacin succinate) tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. The recommended dose of VESIcare is 5 mg once daily. If the 5-mg dose is well tolerated, the dose may be increased to 10 mg once daily.

Important Safety Information

VESIcare is contraindicated in patients with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, and in patients with hypersensitivity to the product.

Angioedema of the face, lips, tongue and/or larynx have been reported with VESIcare. Cases of angioedema have been reported to occur hours after the first dose or after multiple doses. Angioedema associated with upper airway swelling may be life threatening. If involvement of the tongue, hypopharynx, or larynx occurs, VESIcare should be promptly discontinued and appropriate therapy and/or measures necessary to ensure a patent airway should be promptly provided. Anaphylactic reactions have been reported rarely in patients treated with VESIcare. VESIcare should not be used in patients with a known or suspected hypersensitivity to solifenacin succinate. In patients who develop anaphylactic reactions, VESIcare should be discontinued and appropriate therapy and/or measures should be taken.

VESIcare should be administered with caution to patients with clinically significant bladder outflow obstruction, decreased gastrointestinal motility, controlled narrow-angle glaucoma, or reduced renal or hepatic function. Doses of VESIcare higher than 5 mg are not recommended in patients with severe renal impairment, moderate hepatic impairment, or when administered with ketoconazole or other potent CYP3A4 inhibitors. Use of VESIcare in patients with severe hepatic impairment is not recommended.

Anticholinergic central nervous system (CNS) effects have been reported with VESIcare use, including headache, confusion, hallucinations and somnolence. Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing dose, and be advised not to drive or operate heavy machinery until they know how VESIcare affects them. If a patient experiences these effects, dose reduction or drug discontinuation should be considered.

In placebo-controlled studies, for the 10-mg dose, three intestinal serious adverse events were reported (one fecal impaction, one colonic obstruction, and one intestinal obstruction). For the 5‑mg dose, one serious adverse event (angioneurotic edema) was reported.

In placebo-controlled studies, the most common adverse reactions reported by patients were dry mouth (10.9%, 27.6%, 4.2%), constipation (5.4%, 13.4%, 2.9%), blurred vision (3.8%, 4.8%, 1.8%), and urinary tract infection (2.8%, 4.8%, 2.8%) with VESIcare 5 mg, 10 mg, and placebo, respectively.

Please click here for complete Prescribing Information.

You are now leaving

You are now leaving The website you are linking to is neither owned nor controlled by Astellas. Astellas is not responsible for the content or services on this site.
Continue to Twitter.
As always, the information you give us will not be sold or shared with anyone. Please see our Privacy Policy for more information.

For healthcare professionals only

The information contained on this site is intended for healthcare professionals in the United States only. It is not intended for the general public.